Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Despite promising efficacy, the clinical use of the anti-tubercular therapeutic bedaquiline has been restricted due to safety concerns. To date, limited SAR studies have focused on the quinoline ring (A-ring), and as such, we set out to explore modifications within this region in an attempt to discover new bedaquiline variants with an improved safety profile. We herein report the development of unique synthetic strategies that facilitated access to novel bedaquiline analogues leading to the discovery that anti-tubercular activity could be retained following replacement of the quinoline motif with pyridine heterocycles. This discovery is anticipated to open up multiple new avenues for exploration in the design of improved anti-tubercular therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221263 | PMC |
| http://dx.doi.org/10.1039/d1md00063b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A potent phenylalkylamine disrupts mycobacterial membrane bioenergetics and augments bactericidal activity of bedaquiline.
iScience
July 2025
Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.
Clinically efficacious combination therapies capable of impeding resistance are widely sought for the treatment of mycobacterial infections. Here, we described structural modifications of the phenylalkylamine scaffold of verapamil to give an analog with more than 10-fold greater growth inhibitory activity than verapamil against , BCG, and The analog synergized with the FF-ATP synthase inhibitor bedaquiline in checkerboard assays and augmented the bactericidal properties of bedaquiline against BCG and . Using live cell bioorthogonal imaging techniques, biochemical and genetic assays, the bactericidal activity of the analog is attributed to the perturbation of membrane bioenergetics and disruption of mycobacterial respiration.
View Article and Find Full Text PDFNetupitant Exhibits Potent Activity on Persisters.
ACS Infect Dis
August 2025
Department of Microbiology, University of Washington, Seattle, Washington 98109, United States.
In (Mtb), persisters are genotypically drug-sensitive bacteria that nonetheless survive antibiotic treatment. Persisters contribute to prolonged TB treatment duration and relapse risk, highlighting the need for new therapeutic strategies to effectively eliminate these tolerant subpopulations. In this study, we screened 2,336 FDA-approved compounds to identify agents that enhance the sterilizing activity of standard anti-TB drugs and prevent the regrowth of persisters.
View Article and Find Full Text PDFExtrapolation of lung pharmacokinetics of bedaquiline across species using physiologically-based pharmacokinetic modelling.
Br J Clin Pharmacol
July 2025
Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece.
Aims: BeBedaquiline (BDQ) is a first-in-class diarylquinoline (DARQ) and a potent anti-tuberculosis drug, vital in combating multi-drug resistant tuberculosis (TB). Understanding its lung pharmacokinetics (PK) across species is crucial for effective clinical translation. This study aimed to extrapolate BDQ's lung PK from preclinical species to humans, focusing on healthy and TB-infected lung tissue.
View Article and Find Full Text PDFCatalytic enantioselective total synthesis of antitubercular agents (-)-bedaquiline and (-)-sudapyridine enabled by dynamic kinetic resolution-asymmetric transfer hydrogenation.
Chem Sci
July 2025
College of Chemistry and Chemical Engineering, Jiangxi Normal University Nanchang 330022 China
(-)-Bedaquiline [(-)-BDQ] is considered to be one of the most promising new therapeutic agents for tuberculosis for over 50 years. However, there are limited general and highly stereocontrolled asymmetric synthetic methods available for (-)-BDQ and its analogues due to the challenge of forging their vicinal stereocenters. Herein, we report a concise and stereocontrolled synthetic route to (-)-BDQ in six steps with an overall yield of 34%, integrating a Rh-catalyzed dynamic kinetic resolution-asymmetric transfer hydrogenation (DKR-ATH) with TADDOL-mediated diastereoselective allylation.
View Article and Find Full Text PDFPopulation pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial.
Eur J Pharm Sci
September 2025
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, PR China; Institute of Medical Innovation, Peking University Third Hospital, Beijing, PR China. Electronic address:
Although bedaquiline (BDQ) received conditional approval for multi-drug resistance tuberculosis (MDR-TB), a black box warning was added due to QT prolongation risk. WX-081, a promising second-in-class drug that finished phase II clinical trial, exhibited comparable anti-TB activity and better cardiac safety. The accumulation of its active metabolite WX-081-M3 leads to QT prolongation, whereas the relationships between dosage, exposure and response have not been established.
View Article and Find Full Text PDF